Study Refines Renal Dosing of Daptomycin for Staph BacteremiaStudy Refines Renal Dosing of Daptomycin for Staph Bacteremia
A new study from Novartis Pharma helps quantify the best daptomycin regimen for patients with renal impairment and Staphylococcus aureus (MRSA) bacteremia. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 15, 2013 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
Treatment of Infections Due to Resistant Staphylococcus aureus
This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin–dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC w...
Source: Springer protocols feed by Microbiology - October 6, 2013 Category: Microbiology Source Type: news
Daptomycin in Treating Vancomycin-Resistant Enterococcal UTIDaptomycin in Treating Vancomycin-Resistant Enterococcal UTI
Daptomycin may be a viable therapeutic option in managing vancomycin-resistant enterococcal UTIs. BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 4, 2013 Category: Consumer Health News Tags: Urology Journal Article Source Type: news
Glass Bits Force Recall of Daptomycin
(MedPage Today) -- Four lots of the intravenous antibiotic drug daptomycin (Cubicin) have been recalled because of glass particles found in some vials, the FDA and the drug's manufacturer said. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 30, 2013 Category: Primary Care Source Type: news
Cubicin (daptomycin for injection): Recall - Glass Particulate Matter Present in Four Lots
Risk of thromboembolism and pulmonary
emboli, some life-threatening. (Source: FDA MedWatch)
Source: FDA MedWatch - August 29, 2013 Category: American Health Source Type: news
Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Four Lots of Cubicin (Daptomycin for Injection) 500mg in 10ml Single Use Vials Due to Presence of Particulate Matter
Lexington, Mass. – Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling four lots of CUBICIN® (daptomycin for injection) to the user level due to the presence of particulate matter found in a number of vials from these lots. No adverse events have been reported to date in association with a product complaint of vials containing glass particulates. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 29, 2013 Category: Food Science Source Type: news
Daptomycin Use in Infants and ChildrenDaptomycin Use in Infants and Children
How safe and effective is daptomycin in treating resistant Gram-positive infections in infants and children? Pediatric Pharmacotherapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2013 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news
U.S. Court Ruling Favors Cubist in Patent Case vs HospiraU.S. Court Ruling Favors Cubist in Patent Case vs Hospira
A U.S. federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin (daptomycin injection) by Hospira Inc. Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2013 Category: Consumer Health News Tags: Pharmacist News Source Type: news
Early Daptomycin Use May Help in MRSA BacteremiaEarly Daptomycin Use May Help in MRSA Bacteremia
Early daptomycin use may improve outcomes in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia when the vancomycin minimal inhibitory concentration (MIC) is above 1 mcg/L. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 13, 2013 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
SMC accepts ceftaroline fosamil (ZinforoT) for restricted use for adults with complicated skin and soft tissue infections
Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium has accepted ceftaroline fosamil (ZinforoT) for restricted use within NHS Scotland in adults with complicated skin and soft tissue infections.
The SMC restriction applies to use in patients with known or suspected meticillin resistant Staphylococcus aureus (MRSA) infection in the following settings:
. For Gram-positive only infections where vancomycin IV is inappropriate/has not been tolerated or treatment modification is required; and daptomycin IV or linezolid IV is normally...
Source: NeLM - Drug Specific Reviews - January 15, 2013 Category: Drugs & Pharmacology Source Type: news
Daptomycin treats S. aureus bacteremia without nephrotoxicity
NEW YORK (Reuters Health) - Daptomycin, with or without beta-lactams, controls Staphylococcus aureus
bacteremia without worsening renal dysfunction, registry data suggest. (Source: Modern Medicine)
Source: Modern Medicine - January 8, 2013 Category: Journals (General) Source Type: news
